drugset

drugset / Trial / NCT03510416

Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma

NCT03510416 ↗

Phase 2 Unknown 22 enrolled Shanghai Zhongshan Hospital

NaSingle-groupOpen-labelTreatment

Summary

Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization .

Timeline

Start: 2018-05-01
Primary completion: 2019-06-30
Completion: 2019-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rivoceranib	Small molecule	—	—

Indications